Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“ESMO26 Impressive results with a next-generation bispecific ADC!
Phase III PANKU-Breast01: EGFR×HER3-targeting iza-bren improved median PFS in HR+/HER2− metastatic breast cancer (8.2 vs 4.0 months; HR 0.41). However, grade ≥3 treatment-related AEs reached 85.3%.
Key questions:
- Do ESR1, PIK3CA, or PTEN alterations influence response?
- What is the impact of prior ADC exposure?”
You can also read: PANKU-Breast01: Izalontamab Brengitecan Reduces Progression Risk by 59% in HR+/HER2− Advanced Breast Cancer.
